Prati
david rees
david rees
Astex; Organon; Parke Davis; University of Cambridge; AstraZeneca
Potvrđena adresa e-pošte na astx.com
Naslov
Citirano
Citirano
Godina
Organic synthesis provides opportunities to transform drug discovery
DC Blakemore, L Castro, I Churcher, DC Rees, AW Thomas, DM Wilson, ...
Nature chemistry 10 (4), 383-394, 2018
10822018
The role of ligand efficiency metrics in drug discovery
AL Hopkins, GM Keserü, PD Leeson, DC Rees, CH Reynolds
Nature reviews Drug discovery 13 (2), 105-121, 2014
10492014
Fragment-based lead discovery
DC Rees, M Congreve, CW Murray, R Carr
Nature Reviews Drug Discovery 3 (8), 660-672, 2004
10192004
The rise of fragment-based drug discovery
CW Murray, DC Rees
Nature chemistry 1 (3), 187-192, 2009
8712009
Solid-phase organic reactions: a review of the recent literature
PHH Hermkens, HCJ Ottenheijm, D Rees
Tetrahedron 52 (13), 4527-4554, 1996
7461996
A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin‐based synthetic host
A Bom, M Bradley, K Cameron, JK Clark, J Van Egmond, H Feilden, ...
Angewandte Chemie International Edition 41 (2), 265-270, 2002
6332002
Solid-phase organic reactions II: A review of the literature Nov 95–Nov 96
PHH Hermkens, HCJ Ottenheijm, DC Rees
Tetrahedron 53 (16), 5643-5678, 1997
5951997
Fragment-based lead discovery: leads by design
RAE Carr, M Congreve, CW Murray, DC Rees
Drug discovery today 10 (14), 987-992, 2005
4832005
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity
S Howard, V Berdini, JA Boulstridge, MG Carr, DM Cross, J Curry, ...
Journal of medicinal chemistry 52 (2), 379-388, 2009
3772009
The'rule of three'for fragment-based drug discovery: where are we now?
H Jhoti, G Williams, DC Rees, CW Murray
Nature Reviews Drug Discovery 12 (8), 644-644, 2013
3262013
Solid-phase organic reactions III: A review of the literature Nov 96–Dec 97
S Booth, PHH Hermkens, HCJ Ottenheijm, DC Rees
Tetrahedron 54 (51), 15385-15443, 1998
3141998
Cyclodextrin-Derived Host Molecules as Reversal Agents for the Neuromuscular Blocker Rocuronium Bromide: Synthesis and Structure− Activity Relationships
JM Adam, DJ Bennett, A Bom, JK Clark, H Feilden, EJ Hutchinson, ...
Journal of Medicinal Chemistry 45 (9), 1806-1816, 2002
3132002
Experiences in fragment-based drug discovery
CW Murray, ML Verdonk, DC Rees
Trends in pharmacological sciences 33 (5), 224-232, 2012
3002012
Discovery of (2, 4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1, 3-dihydroisoindol-2-yl] methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone …
AJ Woodhead, H Angove, MG Carr, G Chessari, M Congreve, JE Coyle, ...
Journal of medicinal chemistry 53 (16), 5956-5969, 2010
3002010
Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor
TPS Perera, E Jovcheva, L Mevellec, J Vialard, D De Lange, T Verhulst, ...
Molecular cancer therapeutics 16 (6), 1010-1020, 2017
2852017
CI‐977, a novel and selective agonist for the κ‐opioid receptor
JC Hunter, GE Leighton, KG Meecham, SJ Boyle, DC Horwell, DC Rees, ...
British journal of pharmacology 101 (1), 183-189, 1990
1941990
Opportunity knocks: organic chemistry for fragment‐based drug discovery (FBDD)
CW Murray, DC Rees
Angewandte Chemie International Edition 55 (2), 488-492, 2016
1912016
Synthesis of tertiary amines using a polystyrene (REM) resin
AR Brown, DC Rees, Z Rankovic, JR Morphy
Journal of the American Chemical Society 119 (14), 3288-3295, 1997
1561997
A novel linker strategy for solid-phase synthesis
JR Morphy, Z Rankovic, DC Rees
Tetrahedron letters 37 (18), 3209-3212, 1996
1401996
Validity of ligand efficiency metrics
CW Murray, DA Erlanson, AL Hopkins, GM Keserü, PD Leeson, ...
ACS medicinal chemistry letters 5 (6), 616-618, 2014
1302014
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20